Genome & Company (KOSDAQ:314130)
South Korea
· Delayed Price · Currency is KRW 2,675.00
0.00 (0.00%)
Last updated: Jun 27, 2025
Genome & Company Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 |
| Net Income | -19,045 | -20,112 | -47,466 | -51,838 | -34,117 | -30,732 | Upgrade
|
| Depreciation & Amortization | 7,481 | 7,447 | 8,272 | 9,462 | 2,591 | 1,464 | Upgrade
|
| Loss (Gain) From Sale of Assets | 11.4 | 79.51 | 77.11 | -0.69 | 12.93 | 92.58 | Upgrade
|
| Asset Writedown & Restructuring Costs | 8,367 | 8,367 | 2,325 | - | - | - | Upgrade
|
| Loss (Gain) From Sale of Investments | 5.37 | -40.28 | -46.44 | - | - | - | Upgrade
|
| Stock-Based Compensation | 1,778 | 2,342 | 12,066 | 6,083 | 5,566 | 6,753 | Upgrade
|
| Provision & Write-off of Bad Debts | - | - | - | -12.92 | - | - | Upgrade
|
| Other Operating Activities | -7,517 | -8,964 | -4,648 | -3,864 | -1,658 | 4,592 | Upgrade
|
| Change in Accounts Receivable | 215.23 | -459.04 | 1,126 | -1,145 | 11.95 | - | Upgrade
|
| Change in Inventory | -1,659 | -1,898 | -1,694 | -886.4 | -154.36 | - | Upgrade
|
| Change in Accounts Payable | -325.13 | 88.24 | 132.77 | -139.79 | 14.8 | - | Upgrade
|
| Change in Other Net Operating Assets | -1,329 | -3,182 | -2,368 | -1,209 | 1,573 | -326.66 | Upgrade
|
| Operating Cash Flow | -12,017 | -16,331 | -32,224 | -43,550 | -26,159 | -18,157 | Upgrade
|
| Capital Expenditures | -2,114 | -3,970 | -18,853 | -6,849 | -2,875 | -1,504 | Upgrade
|
| Sale of Property, Plant & Equipment | - | - | - | 0.96 | 0.5 | 0.5 | Upgrade
|
| Cash Acquisitions | - | - | - | - | -26,721 | - | Upgrade
|
| Divestitures | - | - | - | - | - | 289.69 | Upgrade
|
| Sale (Purchase) of Intangibles | -166 | -216.34 | -189.09 | -427.29 | -504.78 | -325.02 | Upgrade
|
| Investment in Securities | 9,856 | 15,849 | 4,742 | 7,453 | -29,609 | 3,045 | Upgrade
|
| Other Investing Activities | -251.96 | -112.66 | -1,129 | -99.49 | -100.48 | 673.23 | Upgrade
|
| Investing Cash Flow | 7,324 | 11,551 | -15,430 | 77.52 | -59,810 | 2,179 | Upgrade
|
| Long-Term Debt Issued | - | 5,830 | 32,509 | - | - | - | Upgrade
|
| Long-Term Debt Repaid | - | -568.03 | -2,023 | -1,645 | -820.29 | -428.51 | Upgrade
|
| Net Debt Issued (Repaid) | 5,217 | 5,262 | 30,487 | -1,645 | -820.29 | -428.51 | Upgrade
|
| Issuance of Common Stock | 33.17 | 33.84 | 81.49 | 126.83 | 1,248 | 71,450 | Upgrade
|
| Other Financing Activities | -49.57 | -49.78 | - | 35.61 | 57.69 | 0 | Upgrade
|
| Financing Cash Flow | 5,201 | 5,246 | 30,568 | 78,550 | 17,617 | 98,633 | Upgrade
|
| Foreign Exchange Rate Adjustments | 5,354 | 8,727 | 1,226 | 1,089 | 453.3 | -646.07 | Upgrade
|
| Miscellaneous Cash Flow Adjustments | 0 | 0 | -0 | 0 | -0 | 0 | Upgrade
|
| Net Cash Flow | 5,862 | 9,192 | -15,860 | 36,167 | -67,898 | 82,010 | Upgrade
|
| Free Cash Flow | -14,131 | -20,301 | -51,077 | -50,399 | -29,034 | -19,662 | Upgrade
|
| Free Cash Flow Margin | -47.36% | -73.17% | -357.28% | -357.83% | -6434.20% | -13057.09% | Upgrade
|
| Free Cash Flow Per Share | -459.53 | -666.38 | -1808.70 | -1790.39 | -1080.03 | -1021.03 | Upgrade
|
| Cash Interest Paid | 588.57 | 587.12 | 310.78 | 170.8 | 52.71 | 48.13 | Upgrade
|
| Cash Income Tax Paid | 295.75 | 70.95 | 92.92 | 54.31 | 10.84 | 8.7 | Upgrade
|
| Levered Free Cash Flow | -11,221 | -17,433 | -31,442 | -35,323 | -17,129 | -76,734 | Upgrade
|
| Unlevered Free Cash Flow | -8,750 | -15,220 | -30,355 | -35,213 | -17,095 | -75,961 | Upgrade
|
| Change in Net Working Capital | 2,233 | 5,231 | -5,510 | 4,722 | -2,893 | 64,054 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.